Anzeige
+++100%-Trefferquote des Nachbarn: JETZT WIRD GEBOHRT! Genau jetzt könnten bei dieser Aktie exponentielle Gewinne erzielt werden JETZT WIRD GEBOHRT! Genau jetzt könnten bei dieser Aktie exponentielle Gewinne erzielt werden+++

Publication of unaudited financial statements of Kinarus Therapeutics Holding AG (only) for FY2023 28.02.2024, 07:10 Uhr von EQS News Jetzt kommentieren: 0

Werte zum Artikel
Name Aktuell Diff. Börse

Kinarus Therapeutics Holding AG / Key word(s): Annual Results
Publication of unaudited financial statements of Kinarus Therapeutics Holding AG (only) for FY2023

28-Feb-2024 / 07:10 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.


Ad hoc announcement pursuant to Art. 53 LR

These financial statements published today are unaudited and may be subject to change.

Reader of these financial statements shall not place undue reliance on it. Any decision should be made solely on the basis of the audited financial statements which will supersede these financial statements in its entirety.

Basel, Switzerland, 28 February 2024: Kinarus Therapeutics Holding AG (SIX:KNRS) (“Kinarus Holding”, “KNRS” or the “Company”), a SIX Swiss Exchange listed therapeutic drug development company has released today, in advance of the Extraordinary General Meeting of Kinarus Holding scheduled for Friday, 1 March, 2024 whereas various resolutions relating to the previously announced envisaged Business Combination with Curatis AG (“Curatis”) are proposed to be resolved, the unaudited financial statements of Kinarus Therapeutics Holding AG for FY2023. As Kinarus AG remains in Liquidiation, no consolidated financial statements are published for Kinarus Group for FY2023.

Work on the implementation of the envisaged Business Combination between Kinarus Holding and Curatis AG is ongoing. Subject to the approval of the Extraordinary General Meeting of Kinaurus Holding and other conditions set forth in the transaction agreement signed with Curatis related to the envisaged Business Combination, closing of the Business Combination is expected for the end of April 2024.

About Kinarus

Kinarus AG in Liquidation (www.kinarus.com) was founded in 2017 by experienced pharmaceutical executives in Basel, Switzerland. The Kinarus Group consists of the SIX Swiss Exchange listed Kinarus Therapeutics Holding AG and the operating fully owned subsidiary Kinarus AG in Liquidation. Both Kinarus Therapeutics Holding AG and Kinarus AG in Liquidation have filed for bankruptcy in September 2023 after a financing agreement with a Chinese investment company in May 2023 has not led to the agreed payments. Kinarus AG in Liquidation possesses the exclusive worldwide license to pamapimod, covering all indications, and has patented KIN001, its novel mechanism in combination with pioglitazone.

Kinarus Holding has announced on 29 January 2024 that it has entered into a transaction agreement with Curatis AG regarding a contemplated business combination (as further described in the press release dated 29 January 2024). Curatis AG has settled all liabilities which were filed in the creditors' call (Schuldenruf) of Kinarus Therapeutics Holding AG. Kinarus AG in Liquidation remains in liquidation.

For more information, please visit the company’s website at www.kinarus.com.

Investor Relations Contact:
YUMA Capital 
Thomas Bieri
Managing Partner

Tel: +41 44 575 2001
thomas.bieri@yuma-capital.com

Disclaimer

THIS ANNOUNCEMENT IS NOT AN OFFERING MEMORANDUM OR PROSPECTUS AND IS FOR INFORMATION PURPOSES ONLY. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OF, OR SOLICITATION TO PURCHASE OR SUBSCRIBE FOR, THE SECURITIES REFERRED TO IN THIS ANNOUNCEMENT IN THE UNITED STATES, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN OR IN ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES OF SUCH SECURITIES WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. SUCH SECURITIES HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION, EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN TRANSACTIONS NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF SAID ACT, AND APPLICABLE STATE OR LOCAL SECURITIES LAWS. SUCH SECURITIES ARE NOT BEING OFFERED IN THE UNITED STATES OR TO US PERSONS.



End of Inside Information

1846687  28-Feb-2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1846687&application_name=news&site_id=boersennews
Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer